Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LFCR by emailGet an email when LFCR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LFCR, unsubscribe in one click. Privacy
📣 What LFCR Says Is Next
in 2029 · “Drive margin improvement through operational and cost-containment initiatives 2024 – 2026 2027 – 2028 2029 + On track to achieve ~12% revenue CAGR and >25% Adjusted EBITDA margins in 2029 12 Aggressive and Achievable Growth Strategy”
Company press release, May 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LFCR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LFCR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.